Australian Clinical Labs Limited (ASX:ACL)

Australian Clinical Labs Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	741.27	696.37	697.07	995.6	646.7
Revenue Growth (YoY)	6.45%	-0.10%	-29.98%	53.95%	31.83%
Cost of Revenue	470.41	442.37	445.45	546.98	390.18
Gross Profit	270.86	254	251.62	448.62	256.53
Other Operating Expenses	66.81	63.02	63.65	68.54	40.47
Operating Expenses	202.86	191.45	186.4	174.64	128.53
Operating Income	68	62.55	65.22	273.98	128
Interest Expense	-14.59	-12.18	-13.47	-11.75	-15.13
Interest & Investment Income	0.41	0.5	0.18	0.05	0.08
Other Non Operating Income (Expenses)	-3.78	-4.86	-0.4	-	-18.46
EBT Excluding Unusual Items	50.05	46.01	51.53	262.28	94.49
Merger & Restructuring Charges	-3.08	-6.17	-2.63	-8.94	-
Other Unusual Items	-	-4.65	-3.28	-	-7.83
Pretax Income	48.18	36.37	48.31	254.9	86.65
Income Tax Expense	15.36	12.12	12.27	76.5	26.26
Earnings From Continuing Operations	32.82	24.24	36.04	178.4	60.39
Minority Interest in Earnings	-0.39	-0.31	-0.14	-0.16	-0.02
Net Income	32.43	23.93	35.9	178.24	60.37
Net Income to Common	32.43	23.93	35.9	178.24	60.37
Net Income Growth	35.50%	-33.33%	-79.86%	195.24%	46.34%
Shares Outstanding (Basic)	189	199	201	201	152
Shares Outstanding (Diluted)	190	199	201	201	152
Shares Change (YoY)	-4.63%	-0.82%	-0.18%	32.47%	4.65%
EPS (Basic)	0.17	0.12	0.18	0.89	0.40
EPS (Diluted)	0.17	0.12	0.18	0.88	0.40
EPS Growth	42.09%	-32.77%	-79.82%	122.88%	39.83%
Free Cash Flow	174.39	153.09	136.75	262.84	144.36
Free Cash Flow Per Share	0.92	0.77	0.68	1.30	0.95
Dividend Per Share	0.125	0.120	0.140	0.530	0.142
Dividend Growth	4.17%	-14.29%	-73.58%	271.93%	-1.38%
Gross Margin	36.54%	36.48%	36.10%	45.06%	39.67%
Operating Margin	9.17%	8.98%	9.36%	27.52%	19.79%
Profit Margin	4.38%	3.44%	5.15%	17.90%	9.34%
Free Cash Flow Margin	23.53%	21.98%	19.62%	26.40%	22.32%
EBITDA	81.36	76.31	79.71	286.36	138.19
EBITDA Margin	10.98%	10.96%	11.43%	28.76%	21.37%
D&A For EBITDA	13.35	13.76	14.49	12.37	10.19
EBIT	68	62.55	65.22	273.98	128
EBIT Margin	9.17%	8.98%	9.36%	27.52%	19.79%
Effective Tax Rate	31.88%	33.33%	25.39%	30.01%	30.31%
Revenue as Reported	742.49	697.54	704.76	997.17	644.67

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.